Project Summary

The study suggests that the price of patented medicine in Thailand should be controlled based on equity pricing and outcome pricing. Equity pricing can be estimated from the international reference price and outcome pricing can be evaluated from therapeutic referencing or the pharmacoeconomic price. Moreover, in a case study of 7 medicines granted government license use, it was found that the impact of reducing medical expenditure from those policies implemented in the process of pharmaceutical registration are comparable to goveremment use of licences based on the societal perspective